The U.S. FDA has approved Kresladi from Rocket Pharmaceuticals for patients with Leukocyte Adhesion Deficiency Type I (LAD-I), marking a major milestone for the company and the gene therapy field.
Kresladi is a first-of-its-kind gene therapy designed to correct the underlying genetic defect in LAD-I – an ultra-rare immune disorder that leaves children vulnerable to severe, life-threatening infections.
Approval was granted under the accelerated pathway, supported by strong early clinical data demonstrating meaningful biological and clinical responses.
Clinical Highlights (Phase 1/2):
– 100% overall response rate at 12 months
– Sustained immune system improvement
– Reduction in severe infections
– Manageable safety profile with expected side effects
Kresladi represents:
✔ First gene therapy approved for LAD-I
✔ Proof-of-concept for Rocket’s gene therapy platform
✔ Validation of manufacturing and regulatory strategy after prior setbacks
✔ A critical step toward broader adoption of curative genetic treatments
This approval may serve a small patient population, but its broader impact is significant, demonstrating how gene therapy can deliver transformative outcomes even in ultra-rare diseases.
Kudos to the scientists, clinicians, patients, and families who made this breakthrough possible!
Explore more
🎤 Career – Real career stories and job profiles of life science professionals. Discover current opportunities for students and researchers.
💼 Jobs – The latest job openings and internship alerts across academia and industry.
🛠️ Services – Regulatory support, patent filing assistance, and career consulting services.
